Non-Hodgkin Lymphoma
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) as a conditioning for autologous stem cell transplantation in patients with non-Hodgkin lymphoma.
Detailed description
High-dose conditioning regimens commonly used in patients with non-Hodgkin lymphoma are BEAM (BCNU, etoposide, cytarabine, and melphalan), BEAC (BCNU, etoposide, cytarabine, and cyclophosphamide), CBV (cyclophosphamide, carmustine, and etoposide), and combination regimen with total body irradiation. Three-year progression free survival of patients with non-Hodgkin lymphoma received above high-dose chemotherapy followed by autologous stem cell rescue was reported as 40-50%, which is still unsatisfactory. Busulfan (Bu)-based preparative regimens, which are commonly used with allogeneic stem cell transplantation have also been studied with autologous stem cell transplantation for lymphomas. The development of intravenous busulfan achieved 100% bioavailability bypassing the oral route and increased safety and reliability of generating therapeutic busulfan levels, maximizing efficacy. Recently, one prospective study showed that a combination conditioning regimen of intravenous busulfan, cyclophosphamide, and etoposide was found to be well tolerated and seemed to be effective in patients with aggressive non-Hodgkin lymphoma. Another prospective study for patients with multiple myeloma showed that intravenous busulfan plus melphalan conditioning regimen made no grade 3-4 non-hematologic complication.
Interventions
Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
Sponsors
Inje University
Severance Hospital
Asan Medical Center
Ulsan University Hospital
Seoul National University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a high-intermediate/high risk international prognostic index at a diagnosis or with salvage chemotherapy-sensitive relapse/refractory non-Hodgkin lymphoma * Patients with histologically confirmed T cell or NK cell lymphoma at diagnosis * Patients who have not received therapy with high-dose chemotherapy and stem cell transplantation * Life expectation of at least 3 months * ECOG performance status ≤ 2 * Adequate hepatic function (serum bilirubin less than 2.0 mg/dL, AST and ALT less than three times the upper normal limit) * Adequate renal function (serum creatinine less than 2.0 mg/dL). * Adequate cardiac function (ejection fraction ≥ 45% on MUGA scan or echocardiogram). * Adequate bone marrow function (ANC ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3). * All patients are fully informed about the nature and purpose of this study and informed consent should be given before the start of treatment. All patients should fully understand the right of trial abandon without any disadvantage
Exclusion criteria
* Patients with central nervous system involvement of lymphoma * Patients positive for human immunodeficiency virus * Pregnant or breast feeding woman * Young woman without pregnancy test prior to treatment or pregnancy test reveals positive. * Young woman without a reliable and proper contraceptive method * Man being not willing to contraception * Concurrent history of neoplasm other than non-Hodgkin lymphoma with life expectancy less than 3 months (except for curatively treated non-melanoma skin cancer or in-situ uterine cervix cancer). * History of clinically significant cardiac dysfunction (e.g. congestive heart failure, symptomatic coronary artery disease, medically uncontrolled arrhythmia) or myocardial infarction within 12 months * A psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible. * Significant infection or uncontrolled bleeding * Enrollment of other clinical trials within 4 weeks prior to treatment * Any preexisting medical condition of sufficient severity to prevent full compliance with the study * Patient being not willing to or unable to obey study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | After 3 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | After 3 years | — |
| Response rate according to the International Working Group criteria | After 2 months | — |
| Adverse events | From start of conditioning to discharge | — |
| Pharmacogenetic study | After 3 years | Pharmacogenetic study for predictive or prognostic markers using blood samples |
Countries
South Korea
Contacts
Primary ContactSung-Soo Yoon
Backup ContactWon Sik Lee
Outcome results
None listed